MedTrace Logo

The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

NCT05429554 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-06-23

No results posted yet for this study

Summary

The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and cardiovascular protection in Type 2 Diabetic Patients

Conditions

Interventions

DRUG

Vildagliptin

observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients

Sponsors & Collaborators

  • National Institute of Diabetes and Endocrinology, Egypt

    collaborator UNKNOWN

  • MTI University

    lead OTHER

Principal Investigators

  • Toka Hesham · Bachelor of Pharmacy and Pharmaceutical sciences (Clinical Pharmacy)

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2022-09-30
Completion
2022-09-30
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05429554 on ClinicalTrials.gov